Novel Medicines
Equipped with the unique insights that only intersystems biology provides, Senda is positioned to develop transformative therapeutics in multiple disease categories. Our first programs will advance to in-human trials in early 2022.
Four distinct interspecies mechanisms
We have uncovered an initial set of interspecies mechanisms to target for pharmacological intervention. These focus areas guide which programs we select in order to maximize our chance of success.
Co-opting Interspecies Signaling
Interspecies signaling is the body’s original pharmacy, utilizing evolutionary connections between microbes, plants, and humans to regulate immunity, neural behaviors, and other processes. We are pairing these molecular insights with precisely targeted therapies for safe, potent approaches to treat and prevent disease.
Senda Programs
- Immuno-oncology
- Metabolic disease*
Blocking Toxin Production
Microbes can convert molecules from our diet into toxins, leading to years of toxic exposure if left unchecked. We are leading efforts to block these disease-driving processes.
Senda Programs
- Chronic disease*
Preventing Drug Degradation
Many microbes perceive oral medicines as a food source, and break them down for energy before they can get to human cells. We are using intersystems biology to develop inhibitors of these processes to maintain and extend drug efficacy.
Senda Programs
- Neurology
Co-opting Interspecies Transfer
Microbes and plants have unique tools for exchanging large cargo with human cells. We are leveraging these tools to deliver large biomolecules such as nucleic acids, proteins and peptides for therapeutic purposes, including orally.
Future Therapeutic Areas
- Infectious disease vaccines
- Cancer vaccines
- mRNA therapy
- Oral tolerance
- Oral biologics